# An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment

> **NCT00526877** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Taiwan Ltd** · enrollment: 31 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorders

## Interventions

- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00526877
- **Lead sponsor:** Johnson & Johnson Taiwan Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2014-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526877, "An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00526877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*